Clindamycin/benzoyl peroxide
combination drug
Clindamycin/benzoyl peroxide, sold under the brand name Benzaclin among others, is a topical gel used for the treatment of acne. It is a fixed-dose combination of clindamycin, as the phosphate, an antibiotic; and benzoyl peroxide, an antiseptic.
Common side effects include peeling, itching, and dryness of the skin where the gel was applied.
Clindamycin/benzoyl peroxide was approved for medical use in the United States in December 2000. It is available as a generic medication.
Medical uses
The gel is used on the skin to treat light to medium acne vulgaris in people 12 years and older.
Efficacy
There is an average 52% decrease in inflammatory acne lesions by week 12.
The combination is less effective than benzoyl peroxide/salicylic acid after short-term treatment of two to four weeks, but the two treatments showed similar effectiveness after ten to twelve weeks.
Pregnancy and lactation
Studies on whether or not the use of clindamycin/benzoyl peroxide gels is teratogenic or has adverse effects on nursing infants have not been performed. While oral clindamycin passes into breast milk, no such data are available for clindamycin in gel form.
“Clindamycin/benzoyl peroxide” enters the record as combination drug. Crown Archives preserves that source wording while asking what Clindamycin, benzoyl and peroxide can confirm, complicate or overturn.
Why this record matters
“Clindamycin/benzoyl peroxide” is worth following because a concise public description often conceals a longer documentary argument. Here, Clindamycin, benzoyl and peroxide provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jun 3, 2026. The linked authority identifier is Q4890807. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2000.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Clindamycin/benzoyl peroxide”, its source revision and the description used here.
- Expand the search: follow Clindamycin/benzoyl peroxide primary sources, Clindamycin/benzoyl peroxide archive and Clindamycin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Clindamycin/benzoyl peroxide”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Clindamycin/benzoyl peroxide” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.